This study will advance the investigator's knowledge of the integrated cardiorenal and
humoral physiology in type 2 diabetic patients with and without pre-clinical diastolic
dysfunction, and test a novel therapeutic strategy which may prevent a progression to
symptomatic Stage C heart failure
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Treatments:
LCZ 696 Natriuretic Peptide, Brain Sacubitril and valsartan sodium hydrate drug combination